Types of GnRH Therapies

There are 3 types of GnRH agonist therapy:

  • Monthly injection: Injection therapy may be given a once a month on a regular monthly schedule.1
  • Multiple-times-daily nasal spray: This therapy must be administered either two or three times a day. Each dose consists of two or three sprays per nostril, for a total of eight to nine sprays each day.2
  • Once-yearly implant: SUPPRELIN LA is a small implant that is placed in a child's upper inner arm just under the skin and continually releases the medicine for a full year.3

Your child’s doctor should do tests to make sure your child has central precocious puberty before treating with a GnRH agonist. Only you and your doctor can determine the best treatment option for your child with central precocious puberty.

Next: About SUPPRELIN® LA

References:
1. LUPRON DEPOT-PED [package insert]. North Chicago, IL: Abbott Laboratories; 2010.
2. Synarel [package insert]. New York, NY: Pfizer; 2010.
3. SUPPRELIN LA [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Solutions Inc; 2011.

Indication

SUPPRELIN® LA (histrelin acetate) subcutaneous implant is used for the treatment of children with central precocious puberty (CPP).

Important Safety Information

  • SUPPRELIN LA should not be used by women who are or may become pregnant, and in patients who are allergic to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs. Safety and effectiveness in children under 2 years of age has not been determined.

  • SUPPRELIN LA, like other GnRH agonists, may cause a temporary increase in the blood levels of specific hormones associated with the onset of puberty (estrogen in girls and testosterone in both sexes) during the first week of treatment. This increase may temporarily worsen puberty symptoms during the first week, additionally, you may see new symptoms appear during this period. Within the 4 weeks of treatment with SUPPRELIN LA, hormonal suppression generally occurs and the physical signs of puberty should decrease.

  • Your doctor should monitor the levels of specific hormones associated with puberty progression, 1 month after starting SUPPRELIN LA and then every 6 months thereafter. Every 6-12 months, height and bone age should be also monitored by your doctor.

  • During the clinical trial testing of SUPPRELIN LA, the most common side effects involved the implant site and included temporary bruising, pain, soreness, redness of the skin and swelling.

Please talk with your doctor for more information or if you have any questions.